A Long-Term Study to Assess the Ongoing Safety and Efficacy of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency
Phase of Trial: Phase II
Latest Information Update: 24 Sep 2019
Price : $35 *
At a glance
- Drugs Olipudase alfa (Primary)
- Indications Niemann-Pick disease type B
- Focus Adverse reactions
- Sponsors Sanofi; Sanofi Genzyme
- 14 Jun 2018 Planned number of patients changed from 17 to 25.
- 03 Apr 2018 Planned End Date changed from 1 Oct 2021 to 1 Sep 2023.
- 03 Apr 2018 Planned primary completion date changed from 1 Oct 2021 to 1 Sep 2023.